ArticleFrontiers in pharmacology2024

Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

Jianghua Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.